Johnson & Johnson raises dividend for 64th straight year

Johnson & Johnson has raised its dividend for 64 straight years, extending its status as one of the most reliable income stocks on the market. The company announced another increase in its quarterly payout, maintaining a streak that places it among only nine U.S. firms with over half a century of consecutive dividend growth. At current prices, the drugmaker trades with a forward yield near 2.1%, offering investors roughly $210 annually from a $10,000 stake. That’s modest compared with higher-yielding peers, but the consistency is unmatched.

The streak reflects a deliberate strategy to balance reliable payouts with long-term growth. While J&J remains best known as an income stock, it has shifted in recent years toward oncology and other high-value therapies. Its goal to reach $50 billion in annual cancer drug sales by 2030—becoming a leader in oncology—signals a pivot toward expansion as much as income. The company has backed that ambition with acquisitions like Shockwave Medical and Firefly Bio, pushing total returns up nearly 80% since late 2023. Investors now see J&J as a hybrid: still paying dividends, but priced more like a growth company.

Even so, the dividend itself has grown slowly. Over the past decade, J&J’s payout has climbed about 5.3% per year, a steady but unspectacular pace. That’s enough to outpace inflation and keep shareholders satisfied, especially those seeking low-risk income. The company’s diversified business—spanning pharmaceuticals, medical devices, and consumer health—helps protect the dividend even as individual drugs lose patent protection. Analysts expect the streak to continue, citing a robust pipeline and financial flexibility to fund increases.

For income-focused investors, J&J remains a rare safe harbor. A $10,000 investment today would yield around $210 annually, with potential for modest increases each year. The bigger question is whether the stock is still a bargain. Recent gains and the company’s transformation into a growth engine have left some analysts skeptical about its upside compared with faster-moving picks. Still, for those who value bulletproof dividends over explosive returns, J&J’s track record speaks for itself.